February 19, 2015—In another sign of orphan drugs’ rising prominence in drugmakers’ portfolios, an industry blog reports that the Food and Drug Administration approved 53 percent more orphan products in 2014 than in 2013.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)